Four critical aspects of the proposed research include mouse models: testing Abs designed for improved potency, breadth and/or effector function in a novel in vivo mouse model to assess viral entry, evaluating designed immunogens in human VH germline knock-in mice, determining the basis for HIV resistance using HIV-infected humanized NOD/SCID yc-/- mice, and testing AAV models in humanized NOD/SCID yc-/- mice. First, Dr. Nussenzweig and Dr. Ravetch will develop an in vivo assay to assess the ability of broadly neutralizing antibodies to prevent viral entry in mice bearing human Fc receptors (Aim 1 of Project 1 and Aim 2 of Project 2). HIV neutralization is currently assayed in vitro using TZM-bl cells. This system is based on HIV gpl60 pseudotype viruses that carry a transcriptional activator that induces luciferase. Although the TZM-bl assay provides vital information on neutralizing activity in vitro, it fails to inform about innate effector mechanisms that are likely to be essential for neutralizing activity in vivo. The new proposed in vivo viral entry assay, using HIVr^(flox)Luc mice carrying the ROSA-stop-FloxLuciferase gene and the human CD4 and CCR5 genes, will be used by Dr. Nussenzweig, Dr. Ravetch, and Dr. Bjorkman to assess the impact of antibody specificity and effector function on neutralizing activity in vivo. In addition, we will work with our collaborator Dr. Alexander Ploss who is the head of the Rockefeller University, Memorial Sloan-Kettering Cancer and Weill Cornell Medical College humanized mouse user interest group (HuMIG), to produce humanized mice for experiments proposed in Aim 2 of Project 1 and Aim 3 of Project 2. This will require that we maintain a colony of NOD/SCID yc-/- mice to produce chimeric mice reconstituted with human CD34+ stem cells. The core will perform the human CD34+ stem cell transfers to produce humanized mice for testing bNAbs and defining the basis for HIV resistance (Nussenzweig) and for AAV experiments (Ravetch). Core C will maintain and breed the HIVr^(flox)Luc mice, FcR transgenic mice, and NOD/SCID yc-/- mice and will perform the breeding experiments required to produce hFcR/HIVr^(flox)Luc mice that carry human Fc receptors for the experiments proposed by Dr. Nussenzweig and Dr. Ravetch. Core C will also maintain the human VH germline knock-in mice that will be used in Project 1, Aim 3 to test potential immunogens designed by Dr. Bjorkman in Project 3, Aim 4. In addition Core C will distribute HIVr^(flox)Luc mice to other interested investigators in accordance with our Data Sharing plan and NIH policy.

Public Health Relevance

Core C is essential to the the overall application because it will breed, maintain, monitor, and distribute to researchers the mouse models generated in Projects 1 and 2 and used to evalute the antibodies and potential immunogens created in Projects 2, and 3. Core C will provide humanized mice and other mouse species to researchers for the studies proposed in Projects 1 and 2.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI100148-05
Application #
9208101
Study Section
Special Emphasis Panel (ZAI1-RRS-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
5
Fiscal Year
2017
Total Cost
$291,684
Indirect Cost
Name
California Institute of Technology
Department
Type
Domestic Higher Education
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125
Wang, Haoqing; Barnes, Christopher O; Yang, Zhi et al. (2018) Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host Microbe 24:579-592.e4
Stadtmueller, Beth M; Bridges, Michael D; Dam, Kim-Marie et al. (2018) DEER Spectroscopy Measurements Reveal Multiple Conformations of HIV-1 SOSIP Envelopes that Show Similarities with Envelopes on Native Virions. Immunity 49:235-246.e4
Gautam, Rajeev; Nishimura, Yoshiaki; Gaughan, Natalie et al. (2018) A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med 24:610-616
Cohn, Lillian B; da Silva, Israel T; Valieris, Renan et al. (2018) Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nat Med 24:604-609
Bournazos, Stylianos; Ravetch, Jeffrey V (2017) Fc? Receptor Function and the Design of Vaccination Strategies. Immunity 47:224-233
Freund, Natalia T; Wang, Haoqing; Scharf, Louise et al. (2017) Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci Transl Med 9:
Mayer, Christian T; Gazumyan, Anna; Kara, Ervin E et al. (2017) The microanatomic segregation of selection by apoptosis in the germinal center. Science 358:
Wang, Haoqing; Gristick, Harry B; Scharf, Louise et al. (2017) Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. Elife 6:
Horwitz, Joshua A; Bar-On, Yotam; Lu, Ching-Lan et al. (2017) Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell 170:637-648.e10
Nishimura, Yoshiaki; Gautam, Rajeev; Chun, Tae-Wook et al. (2017) Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543:559-563

Showing the most recent 10 out of 52 publications